TechForce Robotics, Inc., the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics, marking the company’s first operational entry into pharmaceutical and laboratory automation. The deployment fulfills Phase 1 objectives under a joint development agreement designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows.
Laboratory and pharmaceutical operations increasingly face the same challenge that has accelerated automation across industries from manufacturing to hospitality: how to improve efficiency while freeing highly trained personnel to focus on higher-value work. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work, product development, or manufacturing output. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows.
TechForce Robotics is positioning itself to address that opportunity by extending its Robotics-as-a-Service (RaaS) platform into laboratory automation. The company’s LIM-E robot is designed to handle routine logistics such as material transport, sample delivery, and waste removal, allowing laboratory staff to concentrate on critical research and production activities. A new strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications.
The implications of this announcement are significant for the pharmaceutical industry. By automating routine tasks, laboratories can potentially increase throughput, reduce errors, and improve overall operational efficiency. This is particularly important in regulated environments where consistency and documentation are paramount. The successful deployment at Oncotelic Therapeutics could serve as a proof of concept for broader adoption across the pharmaceutical sector, potentially leading to faster drug development and manufacturing cycles.
For investors, the move signals TechForce Robotics’ ability to diversify beyond hospitality automation into higher-margin, high-growth sectors. The company’s RaaS model reduces upfront capital expenditure for clients, making automation more accessible. As the pharmaceutical industry continues to face pressure to innovate while controlling costs, robotics solutions like those offered by TechForce could become increasingly essential.
TechForce Robotics is acting as a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF). The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF. TechMediaWire, a specialized communications platform, provides coverage of pioneering companies driving the future of technology. More information is available at https://www.TechMediaWire.com.
